Connexins in cancer : bridging the gap to the clinic
Aasen, Trond (Hospital Universitari Vall d'Hebron)
Leithe, Edward (Oslo University Hospital. Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital and K.G. Jebsen Colorectal Cancer Research Centre)
Graham, Sheila V. (University of Glasgow. MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences)
Kameritsch, Petra (Ludwig-Maximilians-Universität München and Munich University Hospital. Walter Brendel Centre of Experimental Medicine)
Mayán, María D. (University of A Coruña. CellCOM Research Group, Instituto de Investigación Biomédica de A Coruña (INIBIC), Servizo Galego de Saúde (SERGAS))
Mesnil, Marc (Université de Poitiers. STIM Laboratory, Faculté des Sciences Fondamentales et Appliquées)
Pogoda, Kristin (Ludwig-Maximilians-Universität München and Munich University Hospital. Walter Brendel Centre of Experimental Medicine)
Tabernero, Arantxa (Universidad de Salamanca. Departamento de Bioquímica y Biología Molecular)
Universitat Autònoma de Barcelona

Date:	2019
Abstract:	Gap junctions comprise arrays of intercellular channels formed by connexin proteins and provide for the direct communication between adjacent cells. This type of intercellular communication permits the coordination of cellular activities and plays key roles in the control of cell growth and differentiation and in the maintenance of tissue homoeostasis. After more than 50 years, deciphering the links among connexins, gap junctions and cancer, researchers are now beginning to translate this knowledge to the clinic. The emergence of new strategies for connexin targeting, combined with an improved understanding of the molecular bases underlying the dysregulation of connexins during cancer development, offers novel opportunities for clinical applications. However, different connexin isoforms have diverse channel-dependent and -independent functions that are tissue and stage specific. This can elicit both pro- and anti-tumorigenic effects that engender significant challenges in the path towards personalised medicine. Here, we review the current understanding of the role of connexins and gap junctions in cancer, with particular focus on the recent progress made in determining their prognostic and therapeutic potential.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Cancer therapy ; Diagnostic markers ; Cancer microenvironment
Published in:	Oncogene, Vol. 38 (february 2019) , p. 4429-4451, ISSN 1476-5594

DOI: 10.1038/s41388-019-0741-6
PMID: 30814684

23 p, 3.8 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles